25 search results for: biologics
When is the right time to consider a biologic in patients with CRSwNP?
Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.
Prurigo Nodularis: The Patient Journey
An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
ERS 2024 | IL-33 A Promising Target
Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.
Targeted Approaches to Holistic Management of PN
Professors Matthias Augustin and Sarina Elmariah evaluate how targeted therapies transform the management of prurigo nodularis, addressing the itch-scratch cycle and broader manifestations such as lesions.
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation
Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.
European Academy of Dermatology and Venereology (EADV) 2023 | Berlin
ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.
Global ADVENT FORUM 2023, Dermatology Section | Madrid
New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.
